News | Proton Therapy | May 31, 2018

Continuous arc treatment significantly reduces adverse effects of respiration-induced motion on lung cancer patients

Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer

May 31, 2018 — Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at the recent European Society for Radiotherapy and Oncology (ESTRO) 37 Congress, April 20-24 in Barcelona, Spain.

“Beaumont researchers have invented a new mode of proton therapy for lung cancer,” said Peyman Kabolizadeh, M.D., Ph.D., clinical director, Beaumont Proton Therapy Center in Royal Oak. “A continuous proton arc treatment can significantly reduce the adverse effects of respiration-induced motion on lung cancer treatments. This advancement will also result in a better and lower dose of radiation to adjacent organs.”

Explained Kabolizadeh, “The promising results might lead to interest and future development of the proton arc therapy technique. Beaumont continues to be a center of new treatment development through research.”

Proton therapy is a high-tech alternative to X-ray radiation. A scanning beam of proton radiation with online image guidance offers greater precision to destroy cancerous cells, sparing adjacent healthy tissue with fewer side effects.

Proton therapy uses positively charged atomic particles, traveling up to two-thirds the speed of light, to fight cancer. A cyclotron, or particle accelerator, creates protons from hydrogen molecules. The proton beam is sent to the treatment room through a transport system consisting of magnets, called the beam line, finally arriving in the gantry, a device that rotates around the patient. The beam is directed to the patient through a nozzle that targets the tumor.

While proton therapy is not effective against all cancers, it is effective in treating many solid and localized tumors.

Beaumont’s center is one of just 28 proton therapy centers in the U.S. It is the only operational proton therapy center in Michigan. Beaumont doctors have treated or consulted with patients across Michigan and 11 other states since opening the Proton Therapy Center in 2017.

“Our IBA Proteus One single-room treatment system includes precision technologies,” said Kabolizadeh. “Intensity modulated proton therapy with pencil beam scanning technology and 3-D cone beam CT [computed tomography], can target a tumor within less than a millimeter.”

Pencil beam scanning (PBS) refers to the delivery of protons in a thin beam. Like a pencil, the beam uses back and forth motions to target the treatment area – the shape, size and depth — painting a radiation dose on tumors layer by layer. Compared to X-ray beams, which pass through a patient, proton beams deliver targeted radiation to the tumor and then stop – resulting in no exit dose.

For more information: www.beaumont.org


Related Content

News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
News | Radiology Business

July 3, 2024 — The American Society of Radiologic Technologists has launched the BeRAD Professionalism Award to ...

Time July 03, 2024
arrow
News | Radiation Therapy

July 3, 2024 — Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support ...

Time July 03, 2024
arrow
Subscribe Now